肝细胞癌伴随诊断与靶向及免疫治疗

The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma

肝细胞癌(HCC)发病率高、五年生存率低,中晚期HCC患者可选择的有效治疗手段匮乏。近年随着靶向和免疫治疗药物的相继问世及在多种实体瘤治疗领域的应用,给中晚期HCC患者治疗带来了新的选择和获益。伴随诊断随靶向药物的发展应运而生,其在优选特定靶向/免疫治疗药物的适用患者群体及改善治疗预后中的作用愈发凸显。现针对HCC靶向及免疫治疗相关的伴随诊断技术及应用予以述评,以期对HCC的临床精准诊疗有所启示。

Hepatocellular carcinoma(HCC)has a high incidence and low five-year survival rate in China.There is a lack of effective therapeutic approaches available for unresectable patients with advanced HCC.Recently,the development of targeted and immunotherapy agents and their application in the therapy of various solid tumors have brought new options and benefits to patients with advanced HCC.Companion diagnostics(CDx)emerged with the development of targeted agents,and its roles in selecting eligible patients for specific targeted/immunotherapy agents and improving prognosis are getting more prominent.This article focuses on the CDx technologies and applications related to HCC targeting and immunotherapy,in order to provide inspiration for the precise diagnosis and treatment of HCC.